PRGO or NEOG: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical - Products stocks have likely encountered both Perrigo (PRGO) and Neogen (NEOG). But which of these two stocks is more attractive to value investors?
Should Value Investors Buy Perrigo (PRGO) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Perrigo: The Rebound Is Just Getting Started
Perrigo Company remains substantially undervalued, with a Buy rating justified by strong income and growth potential. Recent quarterly EPS and revenue beats, coupled with market share gains, signal improving fundamentals despite a soft OTC market. Management's focus on cost control, debt reduction, and dividend growth underpins a compelling 16–21% expected annual total return.
PRGO vs. NEOG: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Products stocks have likely encountered both Perrigo (PRGO) and Neogen (NEOG). But which of these two companies is the best option for those looking for undervalued stocks?
Are Investors Undervaluing Perrigo (PRGO) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Perrigo Q2 Earnings Call Highlights
Perrigo NYSE: PRGO reported second-quarter 2026 results that exceeded its internal earnings expectations, while sales declined amid soft consumer self-care categories, retailer inventory reductions and a slower start to seasonal demand. The company maintained its full-year outlook, citing improving category trends, market-share gains and expected second-half contributions from innovation, distribution and demand-generation efforts.
Perrigo Stock Rises 23% as Q2 Earnings & Sales Beat Estimates
PRGO tops Q2 EPS estimates as Infant Formula sales jump, helping offset softer demand and divestiture impacts while the company reaffirms 2026 guidance.
Perrigo Company plc (PRGO) Q2 2026 Earnings Call Transcript
Perrigo Company plc (PRGO) Q2 2026 Earnings Call Transcript
Perrigo (PRGO) Reports Q2 Earnings: What Key Metrics Have to Say
The headline numbers for Perrigo (PRGO) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Perrigo (PRGO) Surpasses Q2 Earnings and Revenue Estimates
Perrigo (PRGO) came out with quarterly earnings of $0.5 per share, beating the Zacks Consensus Estimate of $0.31 per share. This compares to earnings of $0.57 per share a year ago.
Perrigo CEO Ousted Over Personal Conduct
Perrigo Chief Executive Patrick Lockwood-Taylor has resigned after the board found his personal conduct had violated company code.
Perrigo: This 11% Yielder Should Cut The Dividend
Perrigo is rated Hold due to a distressed balance sheet, high leverage, and unsustainable dividend coverage. PRGO's 10.9% dividend yield is not covered by free cash flow, with near-term risk of a dividend cut unless further divestitures occur. Recent asset sales, including the Dermacosmetics business, provide short-term relief but dilute margins and highlight the need for portfolio consolidation.
